Dilafor in Brief

Dilafor is a Drug Development Company exploiting New Chemical Entities (NCE) of Low Anticoagulant Heparin (LAH) derivatives.
 
We investigate, document and exploit the pharmacological properties of these derivatives in selected therapeutic areas.

Our approach is to take projects from preclinical research through clinical trials in Phase I to Phase III and file for regulatory approval in major markets. The company draws on the unique and outstanding expertise of our researchers from several fields of interest related to research and drug development.

We have a highly ambitious development plan for our product portfolio and have rapidly surpassed several important milestones.

Dilafor is focused on the delivery of a new generation of pharmaceuticals.